In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma

Keller Lab

Mechanism-based Cancer Therapies


Our utmost goal is to identify and target crucial cancer cell vulnerabilities while sparing normal tissue. From discovery approaches to validation and preclinical testing. Aiming for clinical application.

Cancer originates from normal cells through genetic and epigenetic alterations. By employing forward genomic screening we start from a known gene mutation or cancer-associated condition and investigate the path that results in a manifest malignancy. Major further focus areas of the lab include: oncoprotein-induced disturbance of post-translational protein modifications, in particular SUMOylation, and sensing of DNA damage; constitutively activated B-cell receptor and chemokine receptor signaling; and molecular cancer imaging and theranostics.


Group Leader

Prof. Dr. med. Ulrich Keller


Sarah Al-Tabatabaee, MD Student (Busse group)

Stefanos Bamopoulos, Dr. med., Clinician Scientist                                        

Francis Baumgartner, Dr. med., Clinician Scientist                                          

Marlitt Böger, PhD Student

Antonia Busse, PD Dr. med., Clinician Scientist, Team Leader, Sub-PI

Nese Cakmak, Dr. rer. nat., Scientist (Busse group)

Uta Demel, Dr. med., Clinician Scientist

Falk Fabian, MD Student (Busse group)

Cäcilia Freund, Technical Assistant (Busse group)

Sanket Gosavi, Student

Corinna Grunert, PhD Student (Busse group)

Stefan Habringer, Dr. med. Dr. univ., Clinician Scientist, Team Leader

Gustaaf Heynen, Dr. rer. nat., Scientist

Maximilian Holz, MD Student

Konstandina Isaakidis, M.Sc., Lab Manager

Kaiting Jiang, MD Student

Hazal Köse, PhD Student

Ran Li, MD Student (Busse group)

Hongyu Liu, Dr. rer. medic., Staff Scientist

Anna Meurer, Clinician Scientist

Maja Milanovic, Dr. rer. nat., Scientist

Caroline Anna Peuker, Dr. med., Clinician Scientist (Busse group)

Simone Rhein, Dr. rer. nat., Scientist (Busse group; affiliation EPO GmbH)

Markus Schick, Dr. rer. nat., Associated Scientist

Laura Schmalbrock, Dr. med., Clinician Scientist

Paula Schmidt, MD Student (Busse group)

Veronika Schulze, M.Sc., Technical Assistant

Emina Sivro, PhD Student (Busse group)

Daniel Steiert, PhD Student

Isabelle Träger, MD Student

Sara Uhan, PhD Student

Philine Wegner, PhD Student

Matthias Wirth, PD Dr. rer. nat., Scientist, Team Leader

Sarvenaz Yaghobramzi, MD Student (Busse group)

Chuanbing Zang, Dr. rer. medic., Staff Scientist

Le Zhang, MD Student


Currently, the Keller Group focuses on the following research projects:
Myc-associated cancer biology


Functional genomic screening


Aberrant Ub/SUMO activity in cancer


Chemokine receptor signaling


Functional imaging and theranostics




  • Berlin Institute of Health (BIH)

  • Berliner Krebsgesellschaft

  • Bundesamt für Risikobewertung (BfR)

  • Bundesministerium für Bildung und Forschung (BMBF)

  • Deutsche Forschungsgemeinschaft (DFG)

  • Deutsche Krebshilfe

  • Else Kröner Fresenius Stiftung (EKFS)

  • German Cancer Consortium (DKTK)

  • Sonnenfeld-Stiftung

  • Stiftung Charité

  • Wilhelm-Sander-Stiftung

Research Topics